Ovarian Cancer
Ovarian cancer remains the most lethal gynecologic malignancy, largely due to its silent progression and late-stage diagnosis. Early symptoms are subtle or nonspecific, and current biomarkers such as CA-125 lack the sensitivity and specificity needed for effective screening. As a result, most patients are diagnosed only after the disease has spread beyond the ovaries, when treatment options are limited and survival rates are low. Improving early detection and therapeutic precision is therefore critical. Advances in molecular profiling, proteomics, and extracellular vesicle analysis offer new opportunities to identify biomarkers that reveal disease at its earliest stages and to uncover targets for more effective, personalized therapies.
Ovarian Cancer Research at CR-CHUM
Every website has a story, and your visitors want to hear yours. This space is a great opportunity to give a full background on who you are, what your team does and what your site has to offer. Double click on the text box to start editing your content and make sure to add all the relevant details you want site visitors to know.
If you’re a business, talk about how you started and share your professional journey. Explain your core values, your commitment to customers and how you stand out from the crowd. Add a photo, gallery or video for even more engagement.